Participated · Equity · May 2026

P2 Science develops proprietary, nature-inspired chemical processes to produce renewable specialty ingredients with a focus on performance and sustainability at scale. The company has launched beauty ingredients including Citrolatum® P, a 1:1 plant-based petrolatum replacement, and CitroComplex® Nourish, a natural oil blend for skin and hair, and entered a strategic partnership with Algenesis to develop 100% biobased, biodegradable polyurethanes. P2 has been recognized by Fast Company in 2025 and 2026 and was selected for L'Oréal's L'AcceleratOR sustainable innovation accelerator. It recently received $2.8 million in non-dilutive ARPA-E funding to accelerate catalyst innovation via AI-enhanced autonomous labs. The company plans to use its new equity financing to scale commercial production in beauty and expand its platform into adjacent markets such as aroma technologies, performance polymers, home care, coatings, and crop care. P2 was co-founded by Professor Paul Anastas and Dr. Patrick Foley at Yale's Center for Green Chemistry and Green Engineering and is based in Woodbridge, Connecticut.

Participated · Series B · Aug 2024

Halda Therapeutics is advancing a proprietary RIPTAC™ modality, a heterobifunctional "hold and kill" approach that brings together a cancer-specific protein and an essential protein to selectively kill cancer cells. The company’s lead candidate, HLD-0915, is expected to enter a Phase 1 clinical trial in the first half of 2025 for metastatic, castration-resistant prostate cancer (mCRPC). Halda is also advancing a second RIPTAC program toward clinical development in metastatic breast cancer. Proceeds from the recent financing will support these IND-enabling and early clinical activities, help build the team, and fund additional RIPTAC programs for other indications. The company was founded by Professor Craig Crews of Yale and is located in New Haven, CT. Including the new financing, Halda has raised $202 million to date.

Participated · Equity · Dec 2023

EvolveImmune develops immuno-oncology biologics that provide sustained immune activation while directly targeting tumor cells within a single drug. The company integrates signaling to enable its EVs platform to directly target tumor cells and amplify localized cytokine secretion at tumor sites. Its approach is designed to provide tissue-localized cytokine amplification to maximize tumor cell killing. EvolveImmune positions its EVs as the first biologic to directly target tumor cells and deliver focused cytokine effects in the tumor microenvironment. The article reports the company completed a $37 million financing round, indicating external investor support for its technology. No operating metrics such as revenue or user counts are provided in the article.

Participated · Series A · Sep 2023

CellFE develops a microfluidics-based cell engineering platform focused on advancing development and manufacturing of advanced cell therapies. The platform emphasizes high cell health and payload delivery, streamlined scalability, and automated workflows. Reported benefits include increased cell yield and reduced expansion times, which the company says translate to shorter vein-to-vein times and lower manufacturing costs for advanced cell therapies. The company is led by CEO Alla Zamarayeva and is positioned to support both development and manufacturing workflows. CellFE intends to use recent financing to advance its technology platform and support market launch and growth initiatives. The company is based in Alameda, California. CellFE develops a microfluidics-based device that delivers gene-editing molecules into human cells using rapid cell compressions to drive uptake from the surrounding fluid. Led by CEO Alla Zamarayeva, the company focuses on applying microfluidics to enable engineering of next-generation cell therapies. The company is based in San Carlos, CA. It completed a $4.8M seed financing to accelerate development of its delivery solution. The round was co-led by Dynamk Capital and Cota Capital, with participation from Embark Ventures, Elm Ventures and McEwan Lane Family Trust. Investor representatives Dr. Gustavo Mahler (Dynamk Capital) and Bobby Yazdani (Cota Capital) will join the board of directors.

Led · Series A · May 2022

Allyx Therapeutics was founded in 2018 as a spinout from Yale University and is focused on developing therapies for Alzheimer’s disease. Its lead candidate, ALX-001, is preparing to enter a pivotal Phase 2 clinical trial. The company has raised over $60 million in total funding following a recent $26.5 million financing. Allyx is noted as a Connecticut Innovations portfolio company. The recent capital raise is positioned to support the company’s near-term clinical program for ALX-001. Public commentary around the company emphasizes the high unmet need in dementia and Alzheimer’s among older adults.